RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver
cancer-killing substances without harming normal cells.
PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in
treating patients who have lymphoma or leukemia.
OBJECTIVES: I. Evaluate the efficiency of tumor cell removal by immunomagnetic technique in
patients with B cell malignancies. II. Determine toxicity of mobilized peripheral blood stem
cell (PBSC) components of enriched CD34+ and depleted B cells in this patient population.
III. Compare recovery with the use of this treatment regimen to the use of unmanipulated
PBSC or CD34+ PBSC components in this patient population.
OUTLINE: Patients are assigned to one of two treatment arms for chemotherapy (chemotherapy
protocol following FHCRC-506.2). Patients undergo mobilization and isolation of CD34+ cells
as described in FHCRC-506.2. Peripheral blood stem cells are collected by apheresis and the
CD34+ cells are isolated using magnetic beads. Monoclonal antibodies to CD19 and CD20 are
added to the CD34+ cells to sensitize any remaining tumor cells. Patients undergo
transplantation on day 0, according to applicable transplant protocols, one month after
mobilization. Some patients may receive posttransplant interleukin-2 after achieving durable
engraftment. Patients are followed at day 30, 80, 180, 365, and 395.
PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study.
DISEASE CHARACTERISTICS: Histologically confirmed recurrent B cell malignancy that is
positive for CD19 and/or CD20 antigens Demonstrated or probable tumor cell contamination
of peripheral blood stem cell components No CNS metastases High risk B cell malignancy
indicative of autologous hematopoietic stem cell transplantation No HLA matched donors
Eligible for mobilization of blood stem cells using chemotherapy and G-CSF Eligible for
transplantation on a protocol covering classification and stage of malignancy Intention to
proceed to transplantation within 60 days of peripheral blood stem cell collection
PATIENT CHARACTERISTICS: Age: 70 and under Performance status: Karnofsky 70-100% Life
expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
specified Other: No active infection HIV negative Adequate organ function as defined in
the mobilization and transplant protocols At least 20 CD34+ cells/uL in the peripheral
blood before immunomagnetic separation
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified